Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase III for Prostate Cancer. According to GlobalData, Phase III drugs for Prostate Cancer have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Aglatimagene besadenovec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Aglatimagene besadenovec overview

aglatimagene besadenovec is under development for the treatment of non-small cell lung cancer, high grade glioma. malignant glioma, pediatric malignant glioma including glioblastoma multiforme, recurrent glioblastoma multiforme, anaplastic astrocytoma and recurrent ependymomas, advanced non-metastatic pancreatic adenocarcinoma and prostate cancer. The therapeutic drug candidate consists of (AdV-tk) adenovirus-mediated expression of herpes simplex virus thymidine kinase and valacyclovir in combination with radiation therapy. AdV-tk is administered as intra-tumoral injection and valacyclovir is administered orally. It is developed based on the gene mediated cytotoxic immunotherapy (GMCI) technology.

Candel Therapeutics overview

Candel Therapeutics, formerly Advantagene, is a biopharmaceutical company. It manufactures, develops, and tests cancer immunotherapy drugs and gene-based biologics. Candel Therapeutics offers CAN-2409 and CAN-3110, for the treatment of a broad range of solid tumor indications. It is focused on developing oncolytic viral immunotherapies for the treatment of cancer patients. The company’s oncolytic viral immunotherapy platforms use genetically engineered viruses to induce immunogenic death through viral-mediated cytotoxicity in cancer cells. Its products, CAN-3110 and CAN-2409 are used in the treatment of prostate cancer, brain cancer, pancreatic cancer, lung cancer, malignant pleural effusion, and mesothelioma. Candel Therapeutics is headquartered in Needham, Massachusetts, the US.

For a complete picture of Aglatimagene besadenovec’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.